Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.
International journal of hematologic oncology（2022）
摘要
The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.
更多查看译文
关键词
chronic myeloid leukemia,co-medication use,comorbidity,cytogenetic response,hematologic response,molecular response,survival,tyrosine kinase inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要